ClinicalTrials.gg
CompletedNCT06916091Updated Nov 19, 2025

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

A Phase 1 interventional study of Eloralintide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing eloralintide in Obesity — 13 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.

Enrollment
22nd of 22
30 · median 315
Started
2025
with 3 others
Phase 1
9 of 22
3 open now
Registered
7th of 22
by date
Lead sponsor
22 of 22
Eli Lilly and Company

Among the 22 studies testing eloralintide in Obesity, this one is the 22nd largest by enrollment, is one of 4 that started in 2025, is one of 9 in phase 1, and was the 7th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About eloralintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing eloralintide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it.

The study will last approximately 10 weeks excluding a screening period.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
  • Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed
  • Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization
  • Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not by the investigator
  • Have a (BMI) within the range 27 to 40 kilogram per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Are pregnant, or intend to become pregnant or to breastfeed during the study
  • Have known allergies to related compounds of eloralintide
  • Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the product with minor deviations judged to be acceptable by the investigator:

    • Supine BP > 160/90 millimeter mercury (mmHg)
    • Supine pulse rate \< 50 or > 100 beats per minute (bpm)
    • Orthostatic hypotension
  • Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history
  • Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study
  • Have a history of chronic medical conditions involving the heart, liver, or kidneys
  • Have a medical history or current evidence of cardiac condition
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Eloralintide

    Eloralintide administered subcutaneously (SC)

    Drug: Eloralintide

  • Placebo comparator
    Placebo

    Placebo administered SC

    Drug: Placebo

Interventions

  • Administered subcutaneously (SC)

    Also known as: LY3841136

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to Study Completion (Up to 10 Weeks)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Eloralintide

    PK:Cmax of Eloralintide

    Time frame: Baseline to Study Completion (Up to 10 Weeks)

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of Eloralintide

    PK: AUC of Eloralintide

    Time frame: Baseline to Study Completion (Up to 10 Weeks)

07

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Sep 2025, 4 months.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Apr 21, 2025
Primary completionActual
Sep 9, 2025
CompletionActual
Sep 9, 2025
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06916091
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 21, 2025
Primary completion
Sep 9, 2025
Completion
Sep 9, 2025
Last update
Nov 19, 2025

Study contacts

Contact Lilly at 1-800-LillyRx (1-800-545-5979)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eloralintide

Start the discussion